Publications by authors named "D Sefrioui"
Purpose: Relative dose intensity (RDI) is a measurement of chemotherapy (CT) dose defined as the actual dose received divided by the standard calculated dose during a set period. The study objective was to assess the impact of a RDI ≥ 80% on response and survival of patients treated in first line CT by FOLFOXIRI or FOLFIRINOX ± Bevacizumab (BV) for an unresectable metastatic colorectal cancer (mCRC).
Materials And Methods: It was a retrospective, non-interventional, multicenter study calculating RDI from the first cycles of CT to the first CT-scan evaluation (CT-scan1).
Article Synopsis
- Management of ampullary tumors (AT), which include adenomas (AA) and carcinomas (AC), is tough because there's not a lot of solid research on it.
- The French medical community worked together to create guidelines based on recent studies and expert advice, which categorize recommendations by how strong the evidence is.
- Accurate diagnosis requires special tests, and every patient should have their case reviewed by a team of different doctors before deciding on treatment, with a recommended follow-up period of 5 years.
CONTRIBUTIONS OF MOLECULAR BIOLOGY TO THE MANAGEMENT OF COLORECTAL CANCER. Colorectal cancer (CRC) is a major public health problem affecting almost 43.000 people a year and causing 17.
View Article and Find Full Text PDFAbout 5% of the patients with metastatic colorectal cancers (mCRC) present microsatellite instability (MSI)/deficient mismatch repair system (dMMR). While metastasectomy is known to improve overall and progression-free survival in mCRC, specific results in selected patients with dMMR/MSI mCRC are lacking. Our study aimed to describe metastasectomy results, characterize histological response and evaluate pathological complete response (pCR) rate in patients with dMMR/MSI mCRC.
View Article and Find Full Text PDFBackground: Current knowledge on prognostic biomarkers (especially BRAF /RAS mutations) in metastatic colorectal cancer (mCRC) is mainly based on mCRC patients with proficient mismatch repair (pMMR) tumors. It is uncertain whether these biomarkers have the same prognostic value in mCRC patients with deficient mismatch repair (dMMR) tumors.
Methods: This observational cohort study combined a population-based Dutch cohort (2014-2019) and a large French multicenter cohort (2007-2017).